Content about Wyeth

October 10, 2013

Sales of Hyland’s oral analgesic products are up 23.5% to $15.4 million for the 52 weeks ended Aug. 11 across U.S. multi-outlets, according to IRI. Overall sales trends across the category are down by 1.7%, which suggests that what Hyland’s is doing is right — its products are safe, they work and they aren’t formulated with benzocaine.

Sales of Hyland’s oral analgesic products are up 23.5% to $15.4 million for the 52 weeks ended Aug. 11 across U.S. multi-outlets, according to IRI. Overall sales trends across the category are down by 1.7%, which suggests that what Hyland’s is doing is right — its products are safe, they work and they aren’t formulated with benzocaine.

September 25, 2013

The board of directors of the World Self-Medication Industry on Wednesday named as its chair-elect Erica Mann, member of the Bayer HealthCare executive committee and president of Bayer HealthCare’s Global Consumer Care division.

LEVERKUSEN, Germany — The board of directors of the World Self-Medication Industry on Wednesday named as its chair-elect Erica Mann, member of the Bayer HealthCare executive committee and president of Bayer HealthCare’s Global Consumer Care division. Mann will succeed current chair Zhenyu Guo, CEO, Dihon Pharmaceutical at the completion of his term in June 2014.

June 12, 2013

Pfizer will receive more than $2 billion from Teva Pharmaceutical Industries and Sun Pharmaceutical Industries to settle a case concerning a gastroesophageal reflux disease drug.

NEW YORK — Pfizer will receive more than $2 billion from Teva Pharmaceutical Industries and Sun Pharmaceutical Industries to settle a case concerning a gastroesophageal reflux disease drug.

March 8, 2013

Last year the Food and Drug Administration warned parents against using the ingredient benzocaine in children to relieve oral pain.

SILVER SPRING, Md. — Last year the Food and Drug Administration warned parents against using the ingredient benzocaine in children to relieve oral pain. Children under the age of 2 years who are teething and given benzocaine should be under the supervision of a doctor, the agency warned.

February 8, 2013

A new report by Francesco International identified $35.7 billion worth of potential Rx-to-OTC switches in a wide range of indications, from hypertension and chronic obstructive pulmonary disorder to high cholesterol and erectile dysfunction, and the Food and Drug Administration has been looking at ways technology and pharmacists could be employed to ensure that patients taking drugs new to the consumer health space take them appropriately.

With growth in traditional pharmaceuticals expected to slow down significantly, a growing number of drug makers — branded and generic alike — see specialty drugs as their main sources of revenue for the foreseeable future. At the same time, those drug makers not invested in specialty may be looking for growth opportunities in consumer health.

A new report by Francesco International identified $35.7 billion worth of potential Rx-to-OTC switches in a wide range of indications, from hypertension and chronic obstructive pulmonary disorder to high cholesterol and erectile dysfunction, and the Food and Drug Administration has been looking at ways technology and pharmacists could be employed to ensure that patients taking drugs new to the consumer health space take them appropriately

December 3, 2012

Pfizer on Friday announced that it has completed the sale of its nutrition business to Nestlé for $11.9 billion in cash, following the conclusion of the required regulatory process in most markets.

NEW YORK — Pfizer on Friday announced that it has completed the sale of its nutrition business to Nestlé for $11.9 billion in cash, following the conclusion of the required regulatory process in most markets. In certain countries where completion will be delayed due to ongoing regulatory review, Pfizer will continue to operate the business on an interim basis.

February 21, 2012

A division of Pfizer is asserting that it incurred nearly $1 billion in damages related to the launch of generic versions of one of its drugs.

MUMBAI, India — A division of Pfizer is asserting that it incurred nearly $1 billion in damages related to the launch of generic versions of one of its drugs.

In a lawsuit filed in the U.S. District Court for the District of New Jersey against Sun Pharmaceutical Industries and Teva Pharmaceutical Industries, Wyeth Pharmaceuticals said it estimated that it suffered damages of $960 million from Sun's and Teva's launches of generic versions of the gastroesophageal reflux disease drug Protonix (pantoprazole).

December 23, 2011

Drug makers will focus on patient-specific therapies instead of drugs designed for use by a broad range of people over the next decade, according to a new report released Thursday by Thomson Reuters.

PHILADELPHIA — Drug makers will focus on patient-specific therapies instead of drugs designed for use by a broad range of people over the next decade, according to a new report released Thursday by Thomson Reuters.

The report, titled "The Changing Role of Chemistry in Drug Discovery" and based on drug industry productivity, patent data and other dynamics and trends, was released in recognition of the International Year of Chemistry 2011.

December 2, 2011

Six retailers on Wednesday filed suit naming Wyeth and Teva Pharmaceuticals as defendants and alleging that the defendants unlawfully delayed the entry of generic versions of Wyeth's antidepressant Effexor XR (venlafaxine).

TRENTON, N.J. — Six retailers on Wednesday filed suit naming Wyeth and Teva Pharmaceuticals as defendants and alleging that the defendants unlawfully delayed the entry of generic versions of Wyeth's antidepressant Effexor XR (venlafaxine). A summons was issued to Wyeth and Teva on Thursday.

The retailers include Ahold USA, H-E-B, Kroger, Safeway, Supervalu and Walgreens. The companies are suing for three-times damages plus attorneys fees.

Wyeth was acquired by Pfizer in October 2009.

August 24, 2011

The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


In May, Teva beat out Valeant’s $5.7 billion offer to buy Frazier, Pa.-based Cephalon with a $6.8 billion offer of its own, acquiring Cephalon’s hefty pipeline in the process. And last month, Teva bought Taiyo Pharmaceutical Industry, Japan’s third-largest generics company, for $934 million.


June 15, 2011

Drug Store News has learned that Tim Canning, president of McKesson’s Health Mart division, is leaving the company to take the position of SVP and chief marketing officer at Omnicare. The move is effective June 17.

SAN FRANCISCO — Drug Store News has learned that Tim Canning, president of McKesson’s Health Mart division, is leaving the company to take the position of SVP and chief marketing officer at Omnicare. The move is effective June 17.

“Tim has played an important role in advancing the success of McKesson’s retail independent pharmacy customers through his leadership of key solutions and programs, such as Health Mart,” noted a company representative.

June 8, 2011

With former Wyeth executive Dennis O’Donnell at the helm, Matrixx Initiatives is making a headquarter transition from Phoenix to here in New Jersey, according to a story published in the Arizona Republic earlier this week.

SKILLMAN, N.J. — With former Wyeth executive Dennis O’Donnell at the helm, Matrixx Initiatives is making a headquarter transition from Phoenix to here in New Jersey, according to a story published in the Arizona Republic earlier this week.

The company, however, will maintain offices in Arizona, the report stated.

June 7, 2011

Dr. Reddy's Labs has received regulatory approval from the Food and Drug Administration for generic versions of treatments for Alzheimer's disease, depression and breast cancer.

HYDERABAD, India — Dr. Reddy's Labs has received regulatory approval from the Food and Drug Administration for generic versions of treatments for Alzheimer's disease, depression and breast cancer.

The drug maker said that the FDA approved donepezil hydrochloride tablets, a generic version of Pfizer and Eisai's Arciept, in the 5-mg and 10-mg strengths for the treatment of Alzheimer's disease. Both strengths will be available in 30-, 90- and 500-count bottles.

June 2, 2011

The Food and Drug Administration has approved a generic drug for depression and anxiety made by Mylan, the drug maker said Thursday.

PITTSBURGH — The Food and Drug Administration has approved a generic drug for depression and anxiety made by Mylan, the drug maker said Thursday.

Mylan announced the approval of venlafaxine hydrochloride extended-release capsules in the 37.5-mg, 75-mg and 150-mg strengths.

The drug, used to treat major depressive disorder and social anxiety disorder, is a generic version of Effexor XR, made by Wyeth. Mylan is launching the drug under a licensing agreement it made with Wyeth before its purchase by Pfizer.

March 7, 2011

Actavis last week named Lisa Buono to lead its over-the-counter drug division as part of the company’s strategic expansion of the division.

MORRISTOWN, N.J. — Actavis last week named Lisa Buono to lead its over-the-counter drug division as part of the company’s strategic expansion of the division.

As director of OTC, Buono will oversee the division’s day-to-day operations and will focus on identifying and capitalizing on new product opportunities. Actavis manufactures and distributes numerous nonprescription liquids, creams and ointments sold under the Actavis label and its customers’ own brands, as well as FeverAll brand acetaminophen suppositories.

February 24, 2011

Erica Mann has been named the new head of Bayer HealthCare’s Consumer Care division and member of the Bayer HealthCare executive committee. She will join the company March 14.

LEVERKUSEN, Germany — Erica Mann has been named the new head of Bayer HealthCare’s Consumer Care division and member of the Bayer HealthCare executive committee. She will join the company March 14.

“Over the past 25 years, Mann has become noted in the industry for her strong record of delivering business results,” stated Jörg Reinhardt, Bayer chairman. “Her outstanding experience and insights will further enable [the consumer care division] to take advantage of the sustained growth forecast for the OTC market.”

February 18, 2011



McNeil Consumer Healthcare recently parlayed its Tylenol brand franchise into external analgesics to quite a bit of success. For the four weeks ended Dec. 26, 2010, Precise “from the makers of Tylenol” became the No. 3 best-selling heat patch, with $1.9 million in sales across food, drug and mass (excluding Walmart), according to Symphony­IRI Group. And its pain-relieving cream similarly broke in among the top-selling brands — No. 9 with $1.3 million in sales for the four-week period.

January 28, 2011

The international marketer behind Absorbine and Absorbine Jr. has appointed a new director of marketing.

EAST LONGMEADOW, Mass. — The international marketer behind Absorbine and Absorbine Jr. has appointed a new director of marketing.

Steve Gootzeit, who brings 30 years of experience in marketing and product development to W. F. Young, will be responsible for all aspects of marketing within the company — which markets consumer healthcare products and animal healthcare products — including strategic and brand planning, advertising and managing daily marketing functions within the department.

January 24, 2011

The Food and Drug Administration has approved a treatment for gastroesphageal reflux disease made by a subsidiary of Mylan, the generic drug maker said Monday.

PITTSBURGH — The Food and Drug Administration has approved a treatment for gastroesphageal reflux disease made by a subsidiary of Mylan, the generic drug maker said Monday.

The FDA approved Matrix Labs’ pantoprazole sodium delayed-release tablets in the 20-mg and 40-mg strengths.

The drug is a version of Protonix DR, made by Wyeth, now part of Pfizer. Various versions of the drug had sales of around $1.7 billion during the 12-month period ended in September, according to IMS Health. The FDA also approved a version made by Dr. Reddy’s Labs on Friday.

January 21, 2011

Indian drug maker Dr. Reddy’s Labs has launched a generic treatment for gastroesophageal reflux disease.

HYDERABAD, India — Indian drug maker Dr. Reddy’s Labs has launched a generic treatment for gastroesophageal reflux disease.

The company announced Thursday the launch of pantoprazole sodium delayed-release tablets in the 20-mg and 40-mg strengths. The drug is a version of Protonix, made by Wyeth, now part of Pfizer.

Pantoprazole sodium delayed-release tablets had sales of around $1.8 billion during the 12-month period ended in September 2010, according to IMS Health.

January 18, 2011

Pfizer president and general manager for specialty care and oncology, Geno Germano, will deliver the “State of the Pharma/Biotech Industry Address” at the 2011 Armada Specialty Pharmacy Summit, Armada Health Care said Tuesday.

FLORHAM PARK, N.J. — Pfizer president and general manager for specialty care and oncology, Geno Germano, will deliver the “State of the Pharma/Biotech Industry Address” at the 2011 Armada Specialty Pharmacy Summit, Armada Health Care said Tuesday.

The summit, which will take place in Las Vegas in May, is in its seventh year and is expected to bring 1,500 participants representing 400 specialty healthcare organizations, including specialty pharmacy providers, pharmaceutical and biotech companies, wholesale distributors and others.

January 4, 2011

Pfizer will pay Danish biotech company Santaris Pharma $14 million for access to its development platform for RNA-based therapies, Pfizer said Tuesday.

SAN DIEGO — Pfizer will pay Danish biotech company Santaris Pharma $14 million for access to its development platform for RNA-based therapies, Pfizer said Tuesday.

The drug maker said the deal would expand on an existing one between Hoersholm, Denmark-based Santaris and Wyeth, which Pfizer acquired in 2009. Santaris could take in up to $600 million in milestone payments, as well as royalties on products developed under the collaboration.

December 8, 2010

Johnson & Johnson made its courtship with Dutch biotech company Crucell official by acquiring all of the company for $2.3 billion, the two companies said Wednesday.

NEW BRUNSWICK, N.J. — Johnson & Johnson made its courtship with Dutch biotech company Crucell official by acquiring all of the company for $2.3 billion, the two companies said Wednesday.

In a deal that won the full support of Crucell’s management, J&J will pay $32.74 per share for the remainder of Crucell that it doesn’t already own; J&J indirectly controls around 18% of Crucell’s stock through a Dutch affiliate, while Delta Lloyd Asset Management, Robeco and the Van Herk Group control around 15.5%, according to published reports.

December 6, 2010

Pfizer president and CEO Jeffrey Kindler has retired from the company, the drug maker said Sunday. Ian Read, who currently heads Pfizer’s global biopharmaceutical operations and has worked for the company since 1978, will succeed him.

NEW YORK — Pfizer president and CEO Jeffrey Kindler has retired from the company, the drug maker said Sunday. Ian Read, who currently heads Pfizer’s global biopharmaceutical operations and has worked for the company since 1978, will succeed him.

Kindler cited personal reasons for retiring, saying his around-the-clock work schedule had been “extremely demanding” on him personally, and that he would take time to spend with his family before making his next moves.

November 15, 2010

A former Wyeth executive has been named PepsiCo's EVP global corporate affairs....

PURCHASE, N.Y. — A former Wyeth executive has been named PepsiCo's EVP global corporate affairs.

Tim Cost, who will report to PepsiCo chairman and CEO Indra Nooyi, officially will join the company Dec. 1. In the newly created position, Cost will be responsible for strengthening and protecting PepsiCo's corporate reputation and strategically aligning its communications, public policy, foundation, investor relations, global health and agricultural policy, and regulatory agendas.